Pravastatin limits radiation-induced vascular dysfunction in the skin

Area of Science:

• Oncology
• Vascular Biology
• Radiotherapy

Background:

• Radiation therapy, a common cancer treatment, can cause normal tissue toxicity, particularly skin damage.
• Endothelial dysfunction, linked to reduced nitric oxide availability, is a key factor in radiation-induced vascular injury.
• Statins, like pravastatin, are known for antioxidant and anti-inflammatory properties that may protect endothelial function.

Purpose of the Study:

• To investigate the therapeutic potential of pravastatin in mitigating radiation-induced skin damage.
• To elucidate the role of endothelial nitric oxide synthase (eNOS) in pravastatin's protective effects against radiation injury.

Main Methods:

• Wild type and eNOS(-/-) mice were subjected to dorsal skin irradiation.
• Mice were treated with pravastatin for 28 days post-irradiation.
• Assessed skin lesions, vascular activation, inflammatory markers (CCL2, CXCL1), adhesion molecules (E-selectin, ICAM-1), and eNOS expression.

Main Results:

• Pravastatin treatment significantly improved radiation-induced skin lesions.
• Pravastatin reduced radiation-induced vascular activation by decreasing leukocyte-endothelium interactions.
• Pravastatin limited the increase in inflammatory markers and adhesion molecules, and inhibited inflammatory cell migration.
• Pravastatin preserved eNOS expression, and its beneficial effects were absent in eNOS(-/-) mice.

Conclusions:

• Pravastatin demonstrates a therapeutic effect on radiation-induced skin damage.
• The protective mechanism of pravastatin relies on maintaining endothelial nitric oxide synthase (eNOS) activity.
• Pravastatin represents a promising therapeutic strategy for preventing or reducing radiation-induced skin damage.